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We describe four unrelated children who were referred to two tertiary referral medical genetics units between 1991
and 2005 and who are affected with juvenile polyposis of infancy. We show that these children are heterozygous
for a germline deletion encompassing two contiguous genes, PTEN and BMPR1A. We hypothesize that juvenile
polyposis of infancy is caused by the deletion of these two genes and that the severity of the disease reﬂects
cooperation between these two tumor-suppressor genes.
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Juvenile polyposis syndrome (JPS [MIM 174900]) is a
condition, ﬁrst deﬁned in 1964 by McColl et al.,1 that
predisposes to multiple juvenile hamartomatous polyps
of the gastrointestinal tract. Although the presence of an
isolated juvenile polyp is common in childhood, occur-
ring in perhaps as many as 5% of all children, JPS occurs
in 1 in 100,000 individuals.2 The diagnosis of JPS is of-
ten considered one of exclusion.3 Indeed, other heritable
syndromes with hamartomatous polyps, such as Cow-
den syndrome (CS [MIM 158350]) and Bannayan-Riley-
Ruvalcaba syndrome (BRRS [MIM 153480]) have to be
ruled out ﬁrst.2 Germline heterozygous loss-of-function
mutations of the PTEN gene are identiﬁed in 85% and
65% of patients with CS and BRRS, respectively.4 Sach-
atello et al.5 have deﬁned three types of juvenile poly-
posis: juvenile polyposis coli, generalized juvenile po-
lyposis, and juvenile polyposis of infancy. Juvenile
polyposis coli and generalized juvenile polyposis result
from the variable expression of the same disease, since
some cases of both forms have been reported to segregate
according to a dominant mode in the same family.6 These
conditions are more prevalent in the ﬁrst 2 decades of
life but not before age 6 years for the generalized form.7
Juvenile polyposis of infancy is characterized by its very
early manifestation in the ﬁrst 2 years of life and by a
generalized polyposis with a severe course due to re-
current gastrointestinal bleeding, diarrhea, exudative en-
teropathy, and inanition. The expected lifespan of af-
fected children is therefore limited.5 Only rare cases of
juvenile polyposis of infancy have been reported in the
literature. In contrast to colon-restricted or generalized
juvenile polyposis, for which a family history of the dis-
ease is positive in 20%–50% of cases, individuals with
juvenile polyposis of infancy do not present with a family
history.5,8–12 About 50% of colon-restricted or general-
ized JPS cases are caused by heterozygous germline loss-
of-function mutations, usually point or small size mu-
tations, within the SMAD4 or BMPR1A gene.9–11 So far,
no intragenic germline SMAD4 or BMPR1A mutations
have been identiﬁed in juvenile polyposis of infancy.13
Because of the lack of family history, it was suggested
that juvenile polyposis of infancy is an autosomal re-
cessive condition.5,12 In the present study, we sought to
determine whether JPS is a recessive condition or, in-
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stead, is due to de novo large gene deletions or rear-
rangements that result in such a severe phenotype that
the shortened lifespan is incompatible with childbearing.
The four patients described herein were born from
nonconsanguineous, healthy parents. They all presented
in the ﬁrst months of life with extensive gastrointestinal
juvenile hamartomatous polyposis.
Patient 1 was a girl who presented with macrocephaly
(2 SD) at birth that was more severe (3.5 SD) at age
3 years (table 1). She presented, in the 1st year of life,
with two subcutaneous lipomas of the abdominal wall
and two hemangiomas of the back. She had down-slant-
ing palpebral ﬁssures and a large forehead. No mental
retardation was observed. The severity of gastrointes-
tinal bleeding and diarrhea led to colectomy at age 10
mo. The child died at age 3 years because of recurrent
bleeding and inanition. The extradigestive features of the
disease and, especially, the macrocephaly led to the di-
agnosis of BRRS. A search for a germline mutation of
the PTEN gene by denaturing gradient gel electropho-
resis scanning of the coding sequence did not uncover
any point or small size mutation. Because a de novo
large deletion of the gene was suspected, a segregation
analysis of genetic markers of the PTEN locus (indirect
analysis) from parents to the child was performed and
showed absence of paternal markers (data not shown),
indicating a de novo deletion of the PTEN locus.
Patient 2 is a girl who presented with macrocephaly
(2 SD) at birth that was more severe (6 SD) at age
3 years (table 1). She presented with hypertelorism, ﬂat
nasal bridge, large forehead, low-set ears, and small
mouth and chin. She did not present with cutaneous
abnormalities. No mental retardation was observed. The
severity of bleeding and diarrhea led to colectomy at age
17 mo. The child was 4 years old at the time of the last
observation. She presented with adenomatous polyps
and low-grade dysplasia foci in the small bowel. A search
for point and small size mutations in the coding se-
quences of the PTEN and SMAD4 genes had negative
results. Because of the similarity of this patient’s con-
dition with the disease observed in patient 1, an indirect
analysis of the PTEN locus was also performed, and a
lack of maternal marker contribution was detected (data
not shown), thus indicating a complete hemizygous de-
letion of the PTEN locus.
Patient 3 is a boy who presented with macrocephaly
(2.5 SD) at birth that was less severe at age 13 years
(table 1). He presented with a speckled penis and he-
mangiomas of the abdominal wall. He did not present
with facial dysmorphy. The severity of bleeding and di-
arrhea led to colectomy at age 8 years. He was 14 years
old at the time of the last observation. Foci with severe
dysplasia and an adenocarcinoma located in a polyp
were detected in duodenum. A search for point or small
size mutations in the coding sequences of the PTEN and
SMAD4 genes had negative results. Because parental
DNAs were not available, segregation analysis of PTEN
locus markers was not performed.
Patient 4, whose case was recently reported in brief,
is a girl who presented with macrocephaly in the 1st
year of life (4 SD) (table 1).19 She exhibited frontal
bossing, depressed nasal bridge, and high arched palate
in addition to broad thumbs and toes. Notably, this pa-
tient was found to have atrial and ventricular septal
defects, with atresia of the portal vein. No mental re-
tardation was observed. She presented with 150 juvenile
polyps throughout the entire colon and duodenum by
age 18 mo, which was her age at the last follow-up. A
search for point and small size mutations in PTEN,
BMPR1A, and SMAD4 was performed, with negative
results. However, because it was known that 10% of
patients found to be “negative” for PTEN mutations
have large deletions of PTEN and that these patients
have an excess of hamartomatous polyps, deletion anal-
ysis by quantitative PCR of each exon of PTEN was
performed and revealed a whole-gene deletion (data not
shown).20
In patients 1, 2, and 3, the germline deletion of one
copy of the PTEN locus was conﬁrmed by FISH with
BAC RP11-60C5, encompassing the PTEN gene (ﬁgs.
1A and 2C). In patient 3, however, the deletion was
detected in only 17% of blood-circulating lymphocytes,
indicating that a de novo deletion occurred in the post-
zygote; thus, patient 3 is mosaic for this deletion. We
were not able to determine the percentage of cells car-
rying the PTEN deletion at the digestive-tract level, be-
cause cells from oral mucosa and the upper digestive
tract were not available. Nevertheless, because of the
extent and severity of the polyposis, we hypothesize that
most of the cells of the gastrointestinal tract carry this
deletion.
Since the BMPR1A gene is located on chromosome
10q23, close to the PTEN gene,9 and since the main
feature of the disease associated with BMPR1A muta-
tions is digestive polyposis, we searched in patients 1,
2, and 3 for an associated deletion of the BMPR1A
gene by FISH with BAC RP11-411A19, encompassing
its locus (ﬁgs. 1B, 1C, and 2C). BAC RP11-411A19 gave
two signals: one at the expected BMPR1A locus on
10q23 and another on 10q11.2. The intensity of one
10q23 signal was clearly decreased in the three pa-
tients, in agreement with at least a partial deletion of
the BMPR1A locus. In patient 4, the deletion of the
BMPR1A gene was demonstrated using exon-by-exon
quantitative PCR.19,20 In all four patients, high-resolu-
tion karyotype was normal on the 10q22-q23 region.
Interestingly, however, patient 4 showed cytogenetic ab-
Table 1
Clinical and Genetic Characteristics of Patients with Juvenile Polyposis Who Carry 10q Deletions












Pregnancy Normal Normal Normal Normal ? Normal Normal ? ?
Juvenile polyposis:
Discovered by Rectal bleeding Rectal bleeding Rectal bleeding Rectal bleeding Rectal bleeding Rectal bleeding Rectal bleeding ? ?
Age at onset 1 mo 2.5 mo 3 mo 18 mo 2 years 1 year 18 mo ? ?
Localization Stomachrrectum Stomachrrectum Stomachrrectum Duodenumrpancolonic Duodenumrrectum Colona Duodenum, colon ? ?
Histological nature Hamartomas Hamartomas Hamartomas Hamartomas Hamartomas Hamartomas Hamartomas Hamartomas Hamartomas
Colectomy Yes Yes Yes No (at age 18 mo) ? ? ?  
Macrocephaly 3.5 SD at age
3 years
6 SD at age
3 years
2.5 SD at birth;
2 SD at age
13 years
4 SD   7 SD  ?
Lipoma    ? ? ?  ? ?
Cutaneous abnormalities Hemangiomas  Hemangiomas,
speckled penis
?     ?
Mental retardation         
























Deletion of PTEN         
Deletion of BMPR1A      Probable Probable Probable 
NOTE.—None of these patients had a family history of juvenile polyposis.  p positive ﬁnding;  p negative ﬁnding; ? p unknown.
a Exploration of the upper digestive tract was not mentioned in the case report.
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Figure 1 Deletion of the PTEN and BMPR1A loci evidenced by FISH in patient 2. A, PTEN FISH. The hybridization of BAC RP11-
60C5 (green) and control probe (YAC 889C10, 10qtel) (red) shows, in one chromosome copy, the lack of the BAC RP11-60C5 signal, indicating
the heterozygous deletion of the PTEN locus. B, Scheme of BAC RP11-411A19 hybridization on chromosome arm 10q. BAC RP11-411A19
contains the BMPR1A gene. The speciﬁc signal encompassing the BRMR1A locus is located in 10q23. In addition to the speciﬁc signal, a major
cross-hybridization signal was detected in 10q11.2. When the speciﬁc hybridization signal is missing, a second, minor cross-hybridization signal
appears. It is due to a 25-kb region located 13 Mb centromeric to BMPR1A, which presents 96% homology with a region of BAC RP11-
411A19. C, BMPR1A FISH. The major cross-hybridization signal of BAC RP11-411A19, centromeric to the speciﬁc signal, was used as control
(arrows a and d). The speciﬁc signal (arrow c) appears largely decreased in one chromosome (arrow b), suggesting the complete or partial
deletion of the BMPR1A gene. As mentioned above, the remaining signal is due to a second cross-hybridization (arrow b).
normality 46,XX,t(2;10)(q31;p15), to which cardiac ab-
normalities could be related.
In patient 4, the length of the deletion encompassing
both PTEN and BMPR1A was estimated to be at least
1.2 Mb. The estimation was done using serial micro-
satellite typings and multiple serial semiquantitative
PCR19 (X. P. Zhou and C. Eng, unpublished data). In
patients 1 and 2, we precisely localized the breakpoints
of the deletions and thus their extent by combining
array-based comparative genomic hybridization (array
CGH) at 1-Mb resolution, FISH, and molecular genet-
ics21 (ﬁg. 2). Array CGH showed that the two deletions
were ∼2 Mb long and that they were different but over-
lapping (ﬁg. 2A–2C). The centromeric region in both
cases appeared to be located in BAC RP11-411A19.
Subsequently, in patient 1, we narrowed the region of
the telomeric breakpoint by FISH with BACs RP11-
168O10, RP11-149I23, and RP11-341B24, which is
conserved (ﬁg. 2C). For patient 2, we used BACs RP11-
813O3, RP11-416C17, and RP11-186O14, which is
Figure 2 Deletion breakpoints of patients 1 and 2. A, Scheme of the physical map of the 10q23 region. B, Genes located in the regions of deletion. C, Main BACs used for FISH.
Deleted BACs are red; undeleted BACs are green. D, Junction points deﬁned in patients 1 and 2. For patient 1, the proximal breakpoint is located 2.5 kb upstream of the BMPR1A coding
sequence (chromosome position 88623207), and the telomeric breakpoint is located 5 kb downstream of the ACTA2 gene (chromosome position 90706778). For patient 2, the proximal
breakpoint is located in intron 1 of LDB3 (chromosome position 88421964), and the telomeric breakpoint is located 19 kb downstream of the LIPF gene (chromosome position 90446243).
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conserved (ﬁg. 2C). The centromeric breakpoints were
located in regions of ∼40 and 200 kb in patients 1 and
2, respectively; the telomeric breakpoints were located
in regions of 120 and 220 kb. To further narrow the
breakpoint regions, we used the multiplex PCR/liquid
chromatography method developed by Dehainault et
al.22 In this method, multiple small genomic regions of
200–300 bp are coampliﬁed using unlabeled primers.
Then, PCR products are separated by ion-pair reverse-
phase high-performance liquid chromatography. They
are quantiﬁed by ﬂuorescent detection using a post-
column intercalation dye. The relative peak intensities
for each target directly reﬂect the copy number of each
studied region. By choosing, step by step, a set of 100
pairs of primers for studying the four breakpoint regions,
we were able to narrow the breakpoint regions to ∼5
kb (primer sequences available on request). Also, long-
range PCR was performed for each patient by use of the
forward primer of the ﬁrst centromeric undeleted PCR
fragment of the centromeric breakpoint region and the
reverse primer of the ﬁrst telomeric undeleted PCR frag-
ment of the telomeric breakpoint region. PCR fragments
of 1.4 and 1.7 kb length were obtained for patients 1
and 2, respectively (data not shown). Both fragments
were directly sequenced on both DNA strands, which
allowed the deletion breakpoints to be deﬁned at the
nucleotide level (ﬁg. 2D). According to the Ensembl da-
tabase (version 35), the deletion should span 2,083,571
and 2,024,279 nt for patients 1 and 2, respectively (ﬁg.
2). The analysis of the sequences surrounding the de-
letion breakpoints did not give any clues with respect to
the chromosomal mechanisms involved in the rearrange-
ment. The faint hybridization signal of BAC RP11-
411A19, encompassing the BMPR1A gene on the
deleted chromosome, resulted from a minor cross-
hybridization. Indeed, a region of 25 kb located 13 Mb
centromeric to BMPR1A showed 96% homology with
a region of BAC RP11-411A19 (ﬁg. 1B and 1C).
Thus, in patient 1, from centromere to telomere,
the following genes are deleted: BMPR1A, MMRN2,
SNCG, GLUD1, MINPP1, PAPSS2, PTEN, LIPF, and
ACTA2. In patient 2, the deletion also involves LDB3
in the centromeric region but does not include ACTA2
(ﬁg. 2). The main features of the putative proteins cor-
responding to these genes are described in appendix A
(online only). Moreover, the following transcribed se-
quences are deleted in patient 1: C10orf116, Q5VTM1,
FAM35A, FAM22A, PAPSS2, ATAD1, CFLP1, C10orf59,
ANKRD22, Q9P2H4, and Q8N9Z5. The same tran-
scribed sequences, except forANKRD22, Q9P2H4, and
Q8N9Z5, are also deleted in patient 2. Although we
cannot exclude the role of other genes, we hypothesize
that the deletion of both BMPR1A and PTEN play a
major role in the pathogenesis of the disease in the four
children described here. Also, the role of MINPP1, lo-
cated between PTEN and BMPR1A, deserves to be dis-
cussed. MINPP1 encodes a multiple inositol polyphos-
phate phosphatase that can catalyze similar reactions as
PTEN in vitro, but little is known of its function in
humans in vivo.23 However, the chicken homologue has
been shown to play a role in the maturation and pro-
liferation of chondrocytes,24 and, presumably, a role in
cell growth and differentiation might be attributable to
the function of human MINPP1. Paradoxically, the rat
Minpp1 knockout model only results in rectal prolapse,
without evidence of gastrointestinal polyps or other phe-
notypes.25 Nonetheless, we should not underestimate
what the additive or synergistic role of MINPP1 may be
when considered in the context of conjoint deletion of
BMPR1A and PTEN.
The functions of the PTEN protein include a lipopro-
tein phosphatase activity that downregulates the PI3K/
AKT pathway.26 The PI3K/AKT pathway plays an im-
portant part in the survival, growth, and proliferation
of cells. The BMPR1A gene encodes a type 1 receptor
of the binding proteins of the BMP pathway. This path-
way downregulates cell proliferation, especially the
proliferation of cells of the gastrointestinal tract.27,28
Thus, the deletion of both BMPR1A and PTEN should
lead to increased proliferation of gastrointestinal cells,
through modiﬁcation of the regulation of two different
cellular pathways. Moreover, we hypothesize that the
joint deletion of these two genes has a greater than ad-
ditive effect on the severity of the disease, leading to the
phenotype of juvenile polyposis of infancy. Indeed, mo-
lecular interactions have been documented between the
TGF-b/BMP and the PI3K/AKT pathways. In vitro ex-
posure of the MCF-7 breast cancer cell line to BMP2,
one of the BMPR1A ligands, induces an increase in
PTEN protein levels by inhibiting its proteasome deg-
radation.27 Furthermore, it has been shown that the BMP
pathway downregulates the b-catenin protein level in
intestinal stem cells through positive regulation of
PTEN.28
Many contiguous-gene syndromes have been de-
scribed.29 However, to our knowledge, only one contig-
uous-gene syndrome is associated with a severe expres-
sion of one of the diseases whose gene is deleted, thus
suggesting a cooperative effect between two deleted
genes. The deletion of the TSC2 and PKD1 genes leads
to a severe infantile polycystic kidney disease.30 It should
be noted that TSC2 is the gene involved in tuberosis
sclerosis, a disease deﬁned by the presence of hamar-
tomas. Interestingly, a search for loss of heterozygosity
at the PTEN locus in a few hamartomatous polyps of
both patient 1 and patient 2 showed the retention of the
remaining wild-type allele (data not shown). Although
inactivation of the second allele by mutation or epige-
netic event cannot be excluded, this ﬁnding favors the
hypothesis of a haploinsufﬁcient effect of PTEN and
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BMPR1A in the development of hamartomas, as re-
ported elsewhere.31
The lack of loss of heterozygosity at the hamartoma
level, however, does not preclude a high risk of cancer,
because the loss of the second wild-type allele was pre-
sumably associated with the transformation reported in
the breast tumor of a woman with CS.32 Furthermore,
it is possible that the inactivation of the second allele is
associated with transformation as well, as shown con-
sistently for certain types of sporadic solid tumors, in-
cluding colorectal cancers.33,34 Relatedly, the risk of
colon cancer in individuals with JPS is well known, al-
though not precisely estimated.2 This raises the question
as to whether cancer risk is increased with the deletion
of both BMPR1A and PTEN, compared with the cancer
risk associated with JPS. The detection of grade 3 dys-
plasia foci in patient 2 at age 3 years and the presence
of an adenocarcinoma in patient 3 at age 14 years sug-
gest that the risk of cancer is major.
The disease observed in the four children described
here corresponds to juvenile polyposis of infancy as
described by Sachatello et al.5 So far, no SMAD4 or
BMPR1A point or small size mutations have been iden-
tiﬁed.9–11,13 On the basis of our data, therefore, we pro-
pose that cases of juvenile polyposis of infancy are due
to de novo germline deletions of a chromosomal region
encompassing the PTEN and BMPR1A genes. Indeed,
ﬁve cases in children carrying a deletion of the 10q23
region, identiﬁed by karyotype, have been reported else-
where14–18 (table 1). In the case reported by Tsuchiya et
al.,14 the deletion of both genes was conﬁrmed using
FISH with YAC 771B4 and YAC 738B12, which was
shown to encompass the two genes. These data were
obtained after publication of the case.14 For Zigman et
al.’s case 2, deletion of the BMPR1A locus may be ex-
cluded.18 In the three remaining cases, the cytogenetic
characteristics of the deletionsmake aBMPR1A deletion
probable. Two children, one a carrier and the other
probably a carrier of BMPR1A and PTEN deletions,
were clearly described as affected with juvenile polyposis
of infancy. Both diagnoses were made in the ﬁrst 2 years
of life on the basis of rectal bleeding. Very early onset
of disease and rectal bleeding are hallmarks of juvenile
polyposis of infancy as deﬁned by Sachatello et al.5 (table
1). Moreover, similar to the four cases reported here and
to the four cases presenting with a cytogenetic deletion
compatible with a deletion of the PTEN and BMPR1A
genes, the seven cases of juvenile polyposis of infancy
reported by Sachatello et al.12 are not associated with a
family history. This argues strongly for a de novo de-
letion in each case. It should be noted that Grotsky et
al.35 described a large family with 26 members thought
to be affected with juvenile polyposis. Among them, two
children died before age 4 years due to diarrhea, which
suggests the diagnosis of juvenile polyposis of infancy.
However, data were obtained by retrospective interview,
and the diagnosis of juvenile polyposis of infancy was
uncertain.
The clinical features associated with BRRS (macro-
cephaly, facial dysmorphy, speckled penis, and early-
onset lipomas) were not all present in each patient, al-
though macrocephaly was present in our four patients
(table 1). This is not unexpected, since PTEN gene in-
activation may lead to either BRRS or CS. Most of the
clinical features of CS are absent in childhood and occur
only later in life. Furthermore, three of our four patients
are female and thus cannot manifest speckled penis. The
description of families affected with both CS and BRRS
suggests that modifying factors inﬂuence the expression
of the PTEN gene defect.17 It is thus not surprising that
the clinical presentation of juvenile polyposis of infancy
may alternatively suggest the diagnosis of BRRS or JPS.
Of the seven patients described by Sachatello et al.,12
only two presented with macrocephaly.
In summary, we have shown that the four unrelated
cases of isolated juvenile polyposis of infancy reported
in the present study are due to de novo germline deletions
of 10q encompassing PTEN and BMPR1A. On the basis
of this observation, we suggest that this contiguous gene
deletion is the etiologic basis for the subset of juvenile
polyposis termed “juvenile polyposis of infancy.” To
conﬁrm our hypothesis, it would be interesting to study
at the molecular level the seven cases reported by Sach-
atello et al.,12 as well as other similar cases.
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